Send us a text

Ever wondered how scientists accurately measure brain health across thousands of patients in dozens of countries speaking 30 different languages? That's exactly what Cogstate has mastered over its 25-year journey to become a leader in neuroscience technology.

Brad O'Connor, CEO of Cogstate Limited, takes us behind the scenes of this fascinating ASX-listed company that's quietly revolutionizing how brain health is measured globally. What began as a digital disruptor creating computerized cognitive assessments has evolved into an essential partner for pharmaceutical companies developing new treatments for conditions like Alzheimer's disease, depression, and rare neurological disorders.

The numbers tell a compelling story of innovation driving efficiency. While many companies struggled during the pandemic, Cogstate found ways to do more with less—reducing their workforce by 25% while simultaneously achieving record revenue growth. Their secret? Strategic implementation of AI and advanced analytics that allow them to manage clinical trial endpoints with unprecedented accuracy and at global scale.

Beyond impressive financials—60% gross margins, 20% EBIT margins, and US$34 million in cash with no debt—it's Cogstate's vision for the future that captivates. O'Connor shares how their technology might soon help everyday people assess their cognitive health from home, similar to using a thermometer before deciding whether to see a doctor. With pharmaceutical spending on central nervous system diseases projected to approach oncology levels within a decade, Cogstate stands at the forefront of a massive market opportunity.

Ready to explore how brain health technology is creating both better patient outcomes and compelling investment opportunities? Listen now to discover why Cogstate's digital cognitive tools are becoming indispensable in both clinical research and healthcare settings worldwide.